News
STIM
3.300
+8.91%
0.270
Neuronetics Is Maintained at Buy by BTIG
Dow Jones · 4d ago
Neuronetics Price Target Raised to $6.00/Share From $5.00 by BTIG
Dow Jones · 4d ago
BTIG Maintains Buy on Neuronetics, Raises Price Target to $6
Benzinga · 4d ago
12 Health Care Stocks Moving In Tuesday's Intraday Session
Benzinga · 4d ago
Neuronetics Q2 Earnings Call Highlights
NASDAQ · 4d ago
Neuronetics (STIM) Reports Q2 Loss, Beats Revenue Estimates
NASDAQ · 4d ago
Neuronetics' Q2 Revenue Rises 9%; Adjusted EBITDA Turns Positive, Narrows 2026 Outlook
NASDAQ · 4d ago
Neuronetics narrows losses and boosts margins in Q2
TipRanks · 4d ago
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Benzinga · 4d ago
Neuronetics Narrows FY2026 Sales Guidance from $160.000M-$166.000M to $160.000M-$164.000M vs $161.125M Est
Benzinga · 4d ago
Neuronetics GAAP EPS of -$0.05 beats by $0.07, revenue of $41.57M beats by $1.4M
Seeking Alpha · 4d ago
Neuronetics reports Q2 EPS (5c), consensus (12c)
TipRanks · 4d ago
Weekly Report: what happened at STIM last week (0803-0807)?
Weekly Report · 5d ago
Weekly Report: what happened at STIM last week (0727-0731)?
Weekly Report · 08/03 09:47
Weekly Report: what happened at STIM last week (0720-0724)?
Weekly Report · 07/27 09:50
Neuronetics Appoints Nir Naor CFO; Promotes Cory Anderson To Executive VP
NASDAQ · 07/21 06:07
Top Biotech Gainers: ZYBT Skyrockets, ADVB Drops Planned Offering, STIM Gets New CFO, RDGT On Watch
NASDAQ · 07/21 03:01
Neuronetics Announces New CFO Amid Leadership Transitions
TipRanks · 07/20 20:29
Neuronetics Appoints Naor as CFO
Dow Jones · 07/20 20:29
Neuronetics appoints new CFO
Seeking Alpha · 07/20 20:22
More
Webull provides a variety of real-time STIM stock news. You can receive the latest news about Neuronetics through multiple platforms. This information may help you make smarter investment decisions.
About STIM
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.